You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The UK has given emergency authorization for Pfizer and BioNTech's SARS-CoV-2 vaccine, the Associated Press reports.
A US advisory committee says healthcare workers and nursing home residents should be prioritized to receive a SARS-CoV-2 vaccine, according to the Financial Times.
The Wall Street Journal reports North Korean hackers have targeted half a dozen companies developing SARS-CoV-2 vaccines.
In Cell this week: long-term SARS-CoV-2 shedding, examination of the effects of a coronavirus spike protein mutation, and more.
The Guardian reports that DeepMind Technologies' AlphaFold can predict how proteins fold.
An analysis of blood donations suggests SARS-CoV-2 was present in the US weeks earlier than thought, according to NPR.
CNBC reports that a US Centers for Disease Control and Prevention advisory panel is to vote on how to distribute COVID-19 vaccines.
In PNAS this week: targeting progesterone signaling in ovarian cancer, LINE-1 retrotransposition events in adenocarcinomas, and more.
Moderna is applying for an Emergency Use Authorization for its coronavirus vaccine, according to the New York Times.
Bloomberg reports AstraZeneca may conduct another study of its candidate SARS-CoV-2 vaccine after dosing error.
The National Health Service is to conduct a trial of Grail's blood-based screening test for cancer.
In PLOS this week: somatic mutation patterns of glioblastomas among Lebanese patients, phenome-wide study using UK Biobank data, and more.
Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.
Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.
A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.
In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.
Springer Nature announces €9,500 fee to make papers open-access in Nature and its family of journals.
An early SARS-CoV-2 alteration may have enabled it to spread more easily, according to the New York Times.
Librarians have concluded that notebooks that belonged to Charles Darwin that were thought to have been lost were actually likely stolen, CNN reports.
In PNAS this week: ultrarare variants contribute to aging-related hearing loss, telomeres of cells infected with herpesvirus, and more.
Late-stage testing indicates the AstraZeneca and Oxford University SARS-CoV-2 vaccine can have up to 90 percent efficacy, the Associated Press reports.
NPR reports the US Food and Drug Administration has approved a treatment for a genetic disorder that causes rapid aging.
ScienceInsider reports Nature Communications is reviewing a paper on mentorship following social media criticism arguing it is sexist.
In PLOS this week: method to account for sequencing errors in phylogenies, study of influenza A in Switzerland, and more.
Pfizer and BioNTech announce they are seeking FDA authorization for their candidate SARS-CoV-2 vaccine.